Plasma cortisol and beta-endorphin immunoreactivity in human obesity

Area of Science:

• Endocrinology
• Neuroscience
• Obesity Research

Background:

• The endogenous opioid system and hypothalamic-pituitary-adrenal (HPA) axis are implicated in obesity.
• Previous research has explored the connection between these systems and body weight regulation.

Purpose of the Study:

• To investigate the relationship between the endogenous opioid system, HPA axis, and obesity.
• To examine hormonal levels in obese patients before and during weight loss interventions.

Main Methods:

• Measured morning plasma cortisol and beta-endorphin immunoreactivity in obese patients and normal-weight controls.
• Assessed correlations between hormone levels, body mass index (BMI), and depression ratings.
• Administered dexamethasone to test HPA axis suppression and monitored hormonal changes during a modified protein fast.
• Compared hormonal levels between patients who completed and did not complete a 6-month diet program.

Main Results:

• Obese patients showed no significant differences in baseline plasma cortisol or beta-endorphin compared to controls.
• No correlation was found between weight/BMI and beta-endorphin or cortisol levels in untreated obese patients.
• Plasma cortisol levels correlated with depression ratings in obese patients.
• Dexamethasone suppressed cortisol but not beta-endorphin in most obese patients.
• Weight loss during a modified protein fast led to decreased cortisol levels, while beta-endorphin remained unchanged.
• Patients who failed to complete the diet program had significantly higher plasma beta-endorphin levels.

Conclusions:

• Initial opioid and HPA axis activity does not significantly differ between obese individuals and normal-weight controls.
• Weight loss interventions can alter HPA axis activity, specifically cortisol levels.
• Elevated beta-endorphin levels may be associated with difficulties in adhering to weight loss programs.